Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions

Meta-Analysis of 49 Roche Oncology Trials Comparing Blinded Independent Central Review (BICR) and Local Evaluation to Assess the Value of BICR

(2023) Qinshu Lian et al.   ONCOLOGIST

Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

(2022) Ignace Vergote et al.   LANCET ONCOLOGY

The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value

(2021) Amy Loreen et al.   GYNECOLOGIC ONCOLOGY

Early detection of ovarian cancer

(2020) Rosemarie Forstner   EUROPEAN RADIOLOGY

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

(2019) Antonio González-Martín et al.   NEW ENGLAND JOURNAL OF MEDICINE

Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months

(2018) Stefania Rizzo et al.   EUROPEAN RADIOLOGY

Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour

(2018) Jianrong Zhang et al.   BMJ Open

Exaggeration of PFS by blinded, independent, central review (BICR)

(2018) A Stone et al.   ANNALS OF ONCOLOGY

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

(2018) Kathleen Moore et al.   NEW ENGLAND JOURNAL OF MEDICINE

A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome

(2017) Hebert Alberto Vargas et al.   EUROPEAN RADIOLOGY

FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper

(2017) Thomas J. Herzog et al.   GYNECOLOGIC ONCOLOGY

Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial

(2015) Anne Floquet et al.   GYNECOLOGIC ONCOLOGY

Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials

(2012) Jenny J. Zhang et al.   Therapeutic Innovation & Regulatory Science

Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis

(2011) O. Amit et al.   EUROPEAN JOURNAL OF CANCER

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

(2011) Gordon John Sampson Rustin et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lessons learned from independent central review

(2008) R. Ford et al.   EUROPEAN JOURNAL OF CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?

(2008) Lori E. Dodd et al.   JOURNAL OF CLINICAL ONCOLOGY